早产儿巨细胞病毒感染治疗研究进展  

Advances in the treatment of cytomegalovirus infection in premature infants

作　　者：欧阳珊 周伟 OUYANG Shan;ZHOU Wei(Department of Pharmacy,Guangzhou Women and Children's Medical Center,Guangzhou 510620,Guangdong Province,China;Department of Neonatology,Guangzhou Women and Children's Medical Center Guangzhou 510620,Guangdong Province,China)

机构地区：[1]广州市妇女儿童医疗中心药学部,广东广州510620 [2]广州市妇女儿童医疗中心新生儿科,广东广州510620

出　　处：《世界临床药物》2023年第3期201-207,共7页World Clinical Drug

摘　　要：更昔洛韦(ganciclovir)及其前体药物缬更昔洛韦(valganciclovir)为新生儿巨细胞病毒(cytomegalovirus,CMV)感染的一线用药,但针对早产儿CMV感染的治疗方案目前尚无统一标准。现针对近年来早产儿CMV感染的流行病学、感染筛查、高风险患儿早期识别、治疗指征评估、给药方案及疗程等进行综合分析,以期为临床实践提供参考。Ganciclovir and its precursor valganciclovir are the first-line agents for cytomegalovirus(CMV)infection in neonates.However,there is no unified standard for the treatment of CMV infection in premature infants.This paper comprehensively analyzed the epidemiology,infection screening,early identification of high-risk children,evaluation of treatment indications,administration plan and course of treatment of CMV infection in premature infants in recent years,in order to provide reference for clinical practice.

关 键 词：早产儿 巨细胞病毒 更昔洛韦 缬更昔洛韦 

分 类 号：R722.6[医药卫生—儿科]